OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March.

By providing access to high-quality genomic data linked to rich, longitudinal phenotypic data at scale, Ovation allows life sciences researchers to advance drug discovery and development more ...

“By combining Regeneron’s expertise in genetics and drug development with Truveta's extensive phenotypic data and ... the next generation of drug discovery, as well as enable new approaches ...

Lead antituberculosis (anti-TB) molecules with novel mechanisms of action are urgently required to fuel the anti-TB drug discovery pipeline. Whole-cell phenotypic screening has been employed to ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

The field of drug discovery faces many time-honored challenges. These include high costs, long development times and high rates of failure. The rise of artificial intelligence (AI) technology has been ...